•
Dec 31, 2024

ZEPP Health Q4 2024 Earnings Report

Zepp Health reported a widened net loss in Q4 2024, despite strong sequential revenue growth and improving gross margins.

Key Takeaways

In Q4 2024, Zepp Health generated $59.5M in revenue, up 40% QoQ but down 28% YoY. Despite improved gross margin at 36.8%, a net loss of $36.9M was reported due to one-off non-cash provisions and investment losses.

Revenue reached $59.5M in Q4, up 40% QoQ but down 28.3% YoY.

Gross margin improved to 36.8%, driven by favorable product mix.

Reported net loss of $36.9M due to one-off investment impairments and tax adjustments.

Adjusted net loss stood at $22.5M, the narrowest quarterly loss in 2024.

Total Revenue
$59.5M
Previous year: $84.5M
-29.5%
EPS
-$0.09
Previous year: $0.04
-325.0%
Gross Margin
36.8%
Adjusted Operating Loss
$7.42M
Adjusted Net Loss
$22.5M
Gross Profit
$21.9M
Previous year: $208M
-89.5%
Cash and Equivalents
$111M
Previous year: $146M
-23.9%

ZEPP Health

ZEPP Health

Forward Guidance

Management expects Q1 2025 revenue between $40M and $45M, driven by momentum from Amazfit-branded products.

Positive Outlook

  • Q4 revenue grew 40.2% sequentially
  • Gross margin increased to 36.8% YoY
  • T-Rex 3 and Amazfit brand gaining market traction
  • Refinanced majority of short-term debt into long-term
  • Q1 2025 revenue expected to resume growth

Challenges Ahead

  • Revenue declined 28.3% YoY
  • Net loss widened due to non-cash investment impairments
  • Operating loss of $8.9M in Q4
  • Adjusted net loss of $22.5M in Q4
  • Cash balance decreased by $29M YoY